A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis

Korábbi kezelés

• Have received TYK2 inhibitor and lack of efficacy deemed by investigator
• Topical medications/treatments for psoriasis within 2 weeks prior to administration of any study medication
• Systemic medications/treatments for psoriasis within 4 weeks prior to administration of any study medication
• Has received biological treatment (e.g., anti-TNFα, anti-IL12/23, anti-IL17) for psoriasis less than 5 half-lives of treatment prior to administration of any study medication

Más betegség

• History or risk of tuberculosis (TB)

Laborértékek

• Current or history for drug-induced psoriasis (e.g., psoriasis induced by beta blockers, calcium channel blockers, antimalarial drugs, or lithium)

Egyéb

• Other form of psoriasis (e.g., erythrodermic, pustular or guttate)

• -Stable plaque psoriasis (defined as no morphological or severity changes for ≥ 6 month) and meet the following disease severity at screening and baseline: Total PASI score ≥ 12, and Total sPGA ≥ 3, and Total BSA ≥ 10%
• -Candidate for phototherapy or systemic treatment for plaque psoriasis